stockportfolio.pro
Stocks / CRL vs CYTK
CRL vs CYTK
Charles River Laboratories International, Inc. and Cytokinetics, Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Charles River Laboratories International, Inc. (CRL) | Cytokinetics, Incorporated (CYTK) | |
|---|---|---|
| Market cap | $9.1B | $9.1B |
| Revenue (latest FY) | $4.02B | $88.04M |
| Net income (latest FY) | $-144.34M | $-784.96M |
| Revenue growth (5y CAGR) | 6.5% | 9.5% |
| Net margin | -3.6% | -891.6% |
| Return on equity | -4.6% | 119.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CRL — free Open CYTK — freeFrequently asked questions
Which is bigger, CRL or CYTK?
Charles River Laboratories International, Inc. is larger by market capitalization — $9.1B versus $9.1B.
Which grows faster, CRL or CYTK?
Over the last five fiscal years, Cytokinetics, Incorporated grew revenue faster — 9.5%/yr versus 6.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.